tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2012 Mar 1;8(3). [Epub ahead of print]
Effective influenza vaccines for children: A critical unmet medical need and a public health priority.
Banzhoff A, Stoddard J.
Source
Novartis Vaccines and Diagnostics; Marburg, Germany.
Abstract
Seasonal influenza causes clinical illness and hospitalization in all age groups; however, conventional inactivated vaccines have only limited efficacy in young children. MF59 (?) , an oil-in-water emulsion adjuvant, has been used since the 1990s to enhance the immunogenicity of influenza vaccines in the elderly, a population with waning immune function due to immunosenescence. Clinical trials now provide information to support a favorable immunogenicity and safety profile of MF59-adjuvanted influenza vaccine in young children. Published data indicate that Fluad (?) , a trivalent seasonal influenza vaccine with MF59, was immunogenic and well tolerated in young children, with a benefit/risk ratio that supports routine clinical use. A recent clinical trial also shows that Fluad provides high efficacy against PCR-confirmed influenza. Based on the results of clinical studies in children, the use of MF59-adjuvanted vaccine offers the potential to enhance efficacy and make vaccination a viable prevention and control strategy in this population.
PMID:
22327501
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22327501
Effective influenza vaccines for children: A critical unmet medical need and a public health priority.
Banzhoff A, Stoddard J.
Source
Novartis Vaccines and Diagnostics; Marburg, Germany.
Abstract
Seasonal influenza causes clinical illness and hospitalization in all age groups; however, conventional inactivated vaccines have only limited efficacy in young children. MF59 (?) , an oil-in-water emulsion adjuvant, has been used since the 1990s to enhance the immunogenicity of influenza vaccines in the elderly, a population with waning immune function due to immunosenescence. Clinical trials now provide information to support a favorable immunogenicity and safety profile of MF59-adjuvanted influenza vaccine in young children. Published data indicate that Fluad (?) , a trivalent seasonal influenza vaccine with MF59, was immunogenic and well tolerated in young children, with a benefit/risk ratio that supports routine clinical use. A recent clinical trial also shows that Fluad provides high efficacy against PCR-confirmed influenza. Based on the results of clinical studies in children, the use of MF59-adjuvanted vaccine offers the potential to enhance efficacy and make vaccination a viable prevention and control strategy in this population.
PMID:
22327501
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22327501